Literature DB >> 26278982

Polyglucosan storage myopathies.

Carola Hedberg-Oldfors1, Anders Oldfors2.   

Abstract

Polyglucosan is an amylopectin-like polysaccharide associated with defective glycogen metabolism and, unlike normal glycogen, it is to some extent resistant to α-amylase digestion. It also has a characteristic fibrillar appearance under the electron microscope. Polyglucosan may aggregate into dense inclusions known as polyglucosan bodies. Its accumulation can be found in various tissues to some degree in normal ageing, but it is also the hallmark of some diseases associated with defects in glycogen metabolism. These diseases frequently involve both skeletal and cardiac muscle tissue, causing myopathy with muscle weakness and wasting, and cardiomyopathy with arrhythmia, conduction block, and cardiac failure. Mutations in eight human genes are known to be associated with polyglucosan storage involving muscle, namely GYG1, GBE1, RBCK1 (HOIL-1), PFKM, EPM2A, EPM2B (NHLRC1), PRDM8, and PRKAG2. There is also a common equine polysaccharide storage myopathy belonging to this group of diseases involving the GYS1 gene. The pathogenic mechanisms that cause the abnormal glycogen accumulation appearing as polyglucosan have been studied in some of these diseases. In most cases the pathogenesis is largely unknown. In this review, we summarize the polyglucosan storage diseases from a clinical, morphological, and genetic standpoint. We also identify some important similarities and differences regarding the morphological appearance of polyglucosan accumulation and discuss pathogenic pathways.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cardiomyopathy; Glycogen; Metabolism; Muscle disease; Muscle glycogen storage disorders; Polyglucosan; Polysaccharide storage

Mesh:

Substances:

Year:  2015        PMID: 26278982     DOI: 10.1016/j.mam.2015.08.006

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  23 in total

1.  Late-onset polyglucosan body myopathy in five patients with a homozygous mutation in GYG1.

Authors:  H Orhan Akman; Yavuz Aykit; Ozge Ceren Amuk; Edoardo Malfatti; Norma B Romero; Maria Antonietta Maioli; Rachele Piras; Salvatore DiMauro; Gianni Marrosu
Journal:  Neuromuscul Disord       Date:  2015-11-10       Impact factor: 4.296

2.  Start codon mutation of GYG1 causing late-onset polyglucosan body myopathy with nemaline rods.

Authors:  Giorgio Tasca; Fabiana Fattori; Mauro Monforte; Carola Hedberg-Oldfors; Mario Sabatelli; Bjarne Udd; Renata Boldrini; Enrico Bertini; Enzo Ricci; Anders Oldfors
Journal:  J Neurol       Date:  2016-08-20       Impact factor: 4.849

Review 3.  Skeletal muscle disorders of glycogenolysis and glycolysis.

Authors:  Richard Godfrey; Ros Quinlivan
Journal:  Nat Rev Neurol       Date:  2016-05-27       Impact factor: 42.937

4.  Mutations in genes associated with either myopathy or noncompaction.

Authors:  J Finsterer; C Stollberger
Journal:  Herz       Date:  2018-04-20       Impact factor: 1.443

Review 5.  The 5th International Lafora Epilepsy Workshop: Basic science elucidating therapeutic options and preparing for therapies in the clinic.

Authors:  Matthew S Gentry; Zaid Afawi; Dustin D Armstrong; Antonio Delgado-Escueta; Y Paul Goldberg; Tamar R Grossman; Joan J Guinovart; Frank Harris; Thomas D Hurley; Roberto Michelucci; Berge A Minassian; Pascual Sanz; Carolyn A Worby; Jose M Serratosa
Journal:  Epilepsy Behav       Date:  2020-01-10       Impact factor: 2.937

6.  A highly prevalent equine glycogen storage disease is explained by constitutive activation of a mutant glycogen synthase.

Authors:  C A Maile; J R Hingst; K K Mahalingan; A O O'Reilly; M E Cleasby; J R Mickelson; M E McCue; S M Anderson; T D Hurley; J F P Wojtaszewski; R J Piercy
Journal:  Biochim Biophys Acta Gen Subj       Date:  2016-08-31       Impact factor: 3.770

7.  Lafora Disease and Alpha-Synucleinopathy in Two Adult Free-Ranging Moose (Alces alces) Presenting with Signs of Blindness and Circling.

Authors:  Madhu Ravi; Atilano Lacson; Margo Pybus; Mark C Ball
Journal:  Animals (Basel)       Date:  2022-06-25       Impact factor: 3.231

8.  SGK1 (glucose transport), dishevelled2 (wnt signaling), LC3/p62 (autophagy) and p53 (apoptosis) proteins are unaltered in Lafora disease.

Authors:  Peixiang Wang; Lori Israelian; Yunlin Xue; Siyuan Song; Liliana Attisano; Berge A Minassian
Journal:  All Results J Biol       Date:  2016

9.  Guaiacol as a drug candidate for treating adult polyglucosan body disease.

Authors:  Or Kakhlon; Igor Ferreira; Leonardo J Solmesky; Netaly Khazanov; Alexander Lossos; Rafael Alvarez; Deniz Yetil; Sergey Pampou; Miguel Weil; Hanoch Senderowitz; Pablo Escriba; Wyatt W Yue; H Orhan Akman
Journal:  JCI Insight       Date:  2018-09-06

Review 10.  Lafora disease: Current biology and therapeutic approaches.

Authors:  S Mitra; E Gumusgoz; B A Minassian
Journal:  Rev Neurol (Paris)       Date:  2021-07-21       Impact factor: 4.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.